Odevixibat

(asked on 24th November 2021) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of Odevixibat for treating processive familial intrahepatic cholestasis.


Answered by
Edward Argar Portrait
Edward Argar
Minister of State (Ministry of Justice)
This question was answered on 2nd December 2021

The Department has made no assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based recommendations for the National Health Service on whether licenced medicines represent a clinically and cost-effective use of resources.

NICE is currently appraising odevixibat for the treatment of progressive familial intrahepatic cholestasis through its highly specialised technologies programme and expects to publish final guidance in January 2022.

Reticulating Splines